Sangamo Therapeutics, Inc. NASDAQ:SGMO

Sangamo Therapeutics stock price today

$0.555
-2.00
-78.32%
Financial Health
0
1
2
3
4
5
6
7
8
9

Sangamo Therapeutics stock price monthly change

+462.88%
month

Sangamo Therapeutics stock price quarterly change

+462.88%
quarter

Sangamo Therapeutics stock price yearly change

+376.72%
year

Sangamo Therapeutics key metrics

Market Cap
522.66M
Enterprise value
163.88M
P/E
-1.2
EV/Sales
1.47
EV/EBITDA
-0.98
Price/Sales
2.02
Price/Book
0.76
PEG ratio
0.73
EPS
-1.86
Revenue
18.75M
EBITDA
-133.73M
Income
-328.05M
Revenue Q/Q
-99.69%
Revenue Y/Y
-92.21%
Profit margin
-172.76%
Oper. margin
-180.85%
Gross margin
26.4%
EBIT margin
-180.85%
EBITDA margin
-713.04%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Sangamo Therapeutics stock price history

Sangamo Therapeutics stock forecast

Sangamo Therapeutics financial statements

Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Profit margin
Jun 2023 6.83M -114.50M -1675.29%
Sep 2023 9.39M -104.16M -1108.35%
Dec 2023 2.04M -60.29M -2952.79%
Mar 2024 481K -49.08M -10205.61%
Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Analyst Estimates
Sep 2025 7.75M -15.39M -198.63%
Oct 2025 7.75M -13.82M -178.4%
Dec 2025 34.2M -5.41M -15.82%
Mar 2026 658.25K -23.39M -3553.4%
  • Analysts Price target

  • Financials & Ratios estimates

Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Debt to assets
Jun 2023 325074000 91.43M 28.13%
Sep 2023 219697000 84.77M 38.59%
Dec 2023 165320000 82.43M 49.86%
Mar 2024 128961000 72.26M 56.04%
Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Cash Flow
Jun 2023 -60.71M 42.46M 6.51M
Sep 2023 -47.29M 37.62M -100K
Dec 2023 -50.53M 37.70M 167K
Mar 2024 -48.66M 35.84M 22.12M

Sangamo Therapeutics alternative data

Gene Editing

Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Google Trends - Gene Editing
4 Aug 2024 21
11 Aug 2024 21
18 Aug 2024 20
25 Aug 2024 24
1 Sep 2024 28
8 Sep 2024 28
15 Sep 2024 34
22 Sep 2024 33
29 Sep 2024 30
6 Oct 2024 50
13 Oct 2024 40
20 Oct 2024 31
27 Oct 2024 35
3 Nov 2024 29
10 Nov 2024 34
17 Nov 2024 37
24 Nov 2024 33
1 Dec 2024 40
8 Dec 2024 47
15 Dec 2024 38

Gene Editing Companies

Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Google Trends - Gene Editing Companies
25 Aug 2024 2283317
1 Sep 2024 1172117
8 Sep 2024 862725
15 Sep 2024 942715
22 Sep 2024 1032613
29 Sep 2024 1042616
6 Oct 2024 942527
13 Oct 2024 632115
20 Oct 2024 1102019
27 Oct 2024 1454920
3 Nov 2024 1353624
10 Nov 2024 1243920
17 Nov 2024 642917
24 Nov 2024 1042317
1 Dec 2024 1042721
8 Dec 2024 862528
15 Dec 2024 833429
22 Dec 2024 1144741
29 Dec 2024 40166541
5 Jan 2025 2795543

Types of Gene Editing

Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Google Trends - Types of Gene Editing
5 Mar 2023 01120
12 Mar 2023 01218
19 Mar 2023 1919
26 Mar 2023 0921
2 Apr 2023 1922
9 Apr 2023 02131
16 Apr 2023 11624
23 Apr 2023 11323
30 Apr 2023 11122
7 May 2023 01161
14 May 2023 11338
21 May 2023 1930
28 May 2023 01029
4 Jun 2023 11024
11 Jun 2023 11029
18 Jun 2023 11029
25 Jun 2023 11129
2 Jul 2023 1934
9 Jul 2023 11940
16 Jul 2023 110034

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Job openings
Aug 2023 16
Sep 2023 15
Oct 2023 9
Nov 2023 4
Dec 2023 2
Jan 2024 0
Feb 2024 1
Apr 2024 0
May 2024 0
Jun 2024 1
Jul 2024 0
Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Employee count
Aug 2023 478
Sep 2023 478
Oct 2023 478
Nov 2023 478
Dec 2023 478
Jan 2024 478
Feb 2024 478
Mar 2024 405
Apr 2024 405
May 2024 405
Jun 2024 405
Jul 2024 405

Sangamo Therapeutics other data

38.45% -27.23%
of SGMO is owned by hedge funds
59.35M -44.45M
shares is hold by hedge funds

Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Insider trades (number of shares)
Period Buy Sel
Sep 2023 0 6000000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
BIOGEN INC. 10 percent owner
Common Stock 6,000,000 $0.5 $3,000,000
Sale
BIOGEN INC. 10 percent owner
Common Stock 100,000 $5.27 $526,500
Sale
BIOGEN INC. 10 percent owner
Common Stock 400,000 $5.33 $2,130,800
Purchase
MARKELS JOHN director
Common Stock 6,784 $3.69 $25,026
Purchase
PARKER H STEWART director
Common Stock 5,000 $3.6 $17,995
Sale
BIOGEN INC. 10 percent owner
Common Stock 2,764 $8.51 $23,522
Sale
BIOGEN INC. 10 percent owner
Common Stock 600 $8.56 $5,136
Sale
BIOGEN INC. 10 percent owner
Common Stock 81,187 $8.56 $694,555
Sale
BIOGEN INC. 10 percent owner
Common Stock 23,660 $8.56 $202,553
Sale
BIOGEN INC. 10 percent owner
Common Stock 75,814 $8.64 $654,806
Patent
Application
Filling date: 10 Jan 2022 Issue date: 1 Sep 2022
Grant
Filling date: 17 Apr 2019 Issue date: 23 Aug 2022
Grant
Filling date: 8 Feb 2019 Issue date: 2 Aug 2022
Application
Filling date: 22 Jul 2021 Issue date: 30 Jun 2022
Application
Filling date: 23 Feb 2022 Issue date: 9 Jun 2022
Application
Filling date: 4 Oct 2021 Issue date: 12 May 2022
Grant
Filling date: 29 Apr 2020 Issue date: 26 Apr 2022
Grant
Filling date: 12 Nov 2019 Issue date: 29 Mar 2022
Application
Filling date: 15 Jan 2020 Issue date: 3 Mar 2022
Grant
Filling date: 12 Jul 2018 Issue date: 1 Feb 2022
Insider Compensation
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. (1963) Chief Executive Officer, Pres & Director
$1,200,000
Dr. R. Andrew Ramelmeier Ph.D. (1962) Executive Vice President of Technical Operations
$675,480
Mr. D. Mark McClung (1963) Executive Vice President & Chief Operating Officer
$568,000
Thursday, 19 December 2024
seekingalpha.com
prnewswire.com
Tuesday, 19 November 2024
businesswire.com
Tuesday, 12 November 2024
seekingalpha.com
zacks.com
Monday, 4 November 2024
businesswire.com
Wednesday, 23 October 2024
seekingalpha.com
Tuesday, 22 October 2024
businesswire.com
Monday, 21 October 2024
seekingalpha.com
Tuesday, 24 September 2024
247wallst.com
Tuesday, 6 August 2024
seekingalpha.com
zacks.com
investorplace.com
Wednesday, 24 July 2024
investorplace.com
benzinga.com
Tuesday, 23 July 2024
seekingalpha.com
Thursday, 9 May 2024
seekingalpha.com
Zacks Investment Research
Thursday, 2 May 2024
Business Wire
Monday, 22 April 2024
Business Wire
Tuesday, 12 March 2024
Business Wire
Monday, 8 January 2024
MarketBeat
Thursday, 26 October 2023
Zacks Investment Research
Wednesday, 25 October 2023
Business Wire
Tuesday, 24 October 2023
Business Wire
Wednesday, 20 September 2023
Business Wire
Friday, 25 August 2023
InvestorPlace
Tuesday, 8 August 2023
Zacks Investment Research
Sunday, 16 April 2023
InvestorPlace
Thursday, 23 March 2023
Seeking Alpha
  • What's the price of Sangamo Therapeutics stock today?

    One share of Sangamo Therapeutics stock can currently be purchased for approximately $0.56.

  • When is Sangamo Therapeutics's next earnings date?

    Unfortunately, Sangamo Therapeutics's (SGMO) next earnings date is currently unknown.

  • Does Sangamo Therapeutics pay dividends?

    No, Sangamo Therapeutics does not pay dividends.

  • How much money does Sangamo Therapeutics make?

    Sangamo Therapeutics has a market capitalization of 522.66M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 58.34% to 176.23M US dollars.

  • What is Sangamo Therapeutics's stock symbol?

    Sangamo Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SGMO".

  • What is Sangamo Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Sangamo Therapeutics?

    Shares of Sangamo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Sangamo Therapeutics's key executives?

    Sangamo Therapeutics's management team includes the following people:

    • Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. Chief Executive Officer, Pres & Director(age: 62, pay: $1,200,000)
    • Dr. R. Andrew Ramelmeier Ph.D. Executive Vice President of Technical Operations(age: 63, pay: $675,480)
    • Mr. D. Mark McClung Executive Vice President & Chief Operating Officer(age: 62, pay: $568,000)
  • How many employees does Sangamo Therapeutics have?

    As Jul 2024, Sangamo Therapeutics employs 405 workers.

  • When Sangamo Therapeutics went public?

    Sangamo Therapeutics, Inc. is publicly traded company for more then 25 years since IPO on 6 Apr 2000.

  • What is Sangamo Therapeutics's official website?

    The official website for Sangamo Therapeutics is sangamo.com.

  • Where are Sangamo Therapeutics's headquarters?

    Sangamo Therapeutics is headquartered at 501 Canal Blvd, Brisbane California, CALIFORNIA.

  • How can i contact Sangamo Therapeutics?

    Sangamo Therapeutics's mailing address is 501 Canal Blvd, Brisbane California, CALIFORNIA and company can be reached via phone at +51 09706000.

Sangamo Therapeutics company profile:

Sangamo Therapeutics, Inc.

sangamo.com
Exchange:

NASDAQ

Full time employees:

405

Industry:

Biotechnology

Sector:

Healthcare

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

501 Canal Blvd
Brisbane California, CALIFORNIA 94005

CIK: 0001001233
ISIN: US8006771062
CUSIP: 800677106